Organisation paid for research Program year 2025 Source: CMS Open Payments

Methodist Healthcare Foundation

Neither a doctor nor a teaching hospital

Research payments

$1,599,863

357 payments

Through program year 2025, Methodist Healthcare Foundation is reported as receiving $1,599,863 in research payments, across 357 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$129,498	22
2024	Research	$201,559	26
2023	Research	$148,477	22
2022	Research	$107,678	58
2021	Research	$187,759	74
2020	Research	$316,722	79
2019	Research	$508,171	76

Breakdown

Who paid Research payments · program years 2019–2025

Edwards Lifesciences Corporation $435,634 57 payments
Intercept Pharmaceuticals, Inc. $192,734 61 payments
Veloxis Pharmaceuticals, Inc. $136,479 6 payments
Abbott Laboratories $117,859 61 payments
AstraZeneca UK Limited $89,092 5 payments
AbbVie, Inc. $80,098 17 payments
Medtronic, Inc. $77,141 26 payments
Biogen, Inc. $71,834 3 payments
Gilead Sciences, Inc. $65,612 13 payments
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $59,230 10 payments

Studies the money was for Research payments · program years 2019–2025

The PROGRESS Trial 2021-01 $241,900 22 payments
Alliance 2021-05 $97,057 14 payments
A 12 Month Singlecenter Open Label Randomized Comparative Study to Evaluate Envarsus XL Steroidfree Rabbit Antithymocyte Globulin Induction on Renal Function and Healthrelated Quality of Life Following Liver Transplantation $84,420 4 payments
1011866 $84,259 10 payments
The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre Randomised Double blind Placebo Controlled Phase 3 Extension Study to Characterise the Long term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus $69,323 4 payments
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus $67,179 11 payments
Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) $64,199 2 payments
AdaptResponse $62,998 25 payments
1009742 $58,063 24 payments
Heart Failure Optimization Study $54,180 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.